AzTrials
AzTrials

EndometriosisHYALOENDOQoLNCT04023383

New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery

A study testing 40 cc HyaRegen NCH gel and 40 cc sterile saline solution in people with Endometriosis and Adhesion, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hyaluronan, a glycosaminoglycan found in connective tissues and extracellular matrix, has been postulated to reduce postoperative adhesions, because of its unconditioned biological functions at tissue repair but unfortunately it has a fluid nature that causes rapid degradation, and it cannot effect long enough to work… Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Endometriosis, Adhesion, Quality of Life
What is being tested?
40 cc HyaRegen NCH gel and 40 cc sterile saline solution
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
No sites listed yet
Study dates
1 Jan 2017to 1 Jun 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • aged 18 to 45 years
  • undergoing laparoscopic surgery for suspicious of DIE
  • persistent pain irrespective to any medical treatment

Who cannot join

  • acute or severe infection
  • autoimmune disease
  • known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
  • concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery
  • clinical evidence of cancer
  • use of anticoagulant, fibrin glue, other thromboembolic agents
Show all 9Show fewer
  • use of any other anti-adhesion agent during the procedure
  • patients with surgically diagnosed bowel involvement or need bowel resection
  • patients who want to receive any postoperative hormonal treatment

About this study

Official title: The Effect of New Cross Linked Hyaluronan Gel on Quality of Life of Patients After Deep Infiltrating Endometriosis Surgery: A Randomized Controlled Pilot Study

Hyaluronan, a glycosaminoglycan found in connective tissues and extracellular matrix, has been postulated to reduce postoperative adhesions, because of its unconditioned biological functions at tissue repair but unfortunately it has a fluid nature that causes rapid degradation, and it cannot effect long enough to work as an adhesion barrier.(10,11) For this reason a New cross-linked hyaluronan (NCH) gel, that has higher viscosity compared to natural hyaluronan has been developed by BioRegen Biomedical (Changzhou, Jiangsu, China). It has the ability for gradually absorption within 1 to 2 weeks in vivo, which are the acquired repair period and the critical time for adhesion formation. Although it seems evident that endometriosis has a serious impact on the daily Quality of Life of women; comparable data for the effect of adhesion barriers to patients who have had laparoscopic (Deep infiltrating endometriosis) DIE surgery is missing.

Therefore a pilot randomised controlled study was conducted to evaluate the effect of NCH gel on short term quality of life in patients who had undergone laparoscopic surgery due to DIE.

Read the detailed description

A prospective 1:1 randomised placebo-controlled study was conducted in our department during the study period January 2017-January 2019. All patients were included after obtaining written, signed informed consent before participating. All of the procedures were performed by the same surgery team who are experienced in minimally invasive (Deep infiltrating endometriosis) DIE surgery. The study protocol was approved by the local Ethics Committee of hospital (Approval number: 2017/04/35) 60 patients who were underwent for laparoscopic surgery for the treatment of deep infiltrating endometriosis without bowel involvement were recruited.

The inclusion criteria for this study were as follows, aged 18 to 45 years, and undergoing laparoscopic surgery for suspicious of DIE and persistent pain irrespective to any medical treatment. Patients were booked for follow-up visits at the 3rd and 6th month postoperative months and wanted to fill the questionnaires.

The exclusion criteria for the study were as; acute or severe infection, autoimmune disease, known/suspected intolerance or hypersensitivity to Hyaluronan or its derivatives, concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery, clinical evidence of cancer; use of anticoagulant, fibrin glue, other thromboembolic agents, or any other anti-adhesion agent during the procedure ,patients with surgically diagnosed bowel involvement or need bowel resection, and who want to receive any postoperative hormonal treatment.

Participants were allowed to voluntarily withdraw from the trial for any reason at any time, and could be terminated by investigators owing to safety concerns, violations of inclusion/exclusion criteria, or pregnancy.

Surgical procedure The patients were laid low lithotomy position under general anesthesia. Patients were assigned at random to either the NCH gel or control group in a 1:1 ratio through a computer based program. A standardised technic with 4 abdominal incision laparoscopic approach with 10 mm umbilical trocar for the optic camera and three 5 mm axillary ports for the surgical instruments were used. All of the surgeries initiated from exploring the pelvic cavity, identification of the ureters and dissection transection of the pelvic adhesion by 5 mm bipolar cautery used at 25 kw for coagulation mode and scissors. The incision was begun on the left pelvic sidewall just cephalad to the last deposit. The incision was then extended towards the uterus, lateral and parallel to the left uterosacral ligament. The uterosacral ligament was pushed medially and down and the healthy tissues including the ureter were pushed upwards and laterally away from the dissection. It then transected the right utero-sacral ligament and was continued along the right pelvic sidewall just lateral and above the right uterosacral ligament until it extends beyond all obvious deposits. All of the endometriotic foci was grasped and pulled then undercut and freed so that the whole lesion and a surrounding margin of healthy tissue was removed. After an extensive bleeding control the Patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures. The patients in the control group had 40 cc sterile saline solution compatible with the body temperature. Operators could not be blinded to treatment allocation, but the questionnaire assessors and the patients were blinded to treatment allocation.

Pre and Postoperative assessment of pain and quality of life A dedicated research assisted in this study was asked the validated (visual analogue scale) VAS (dysmenorrhea, dyschezia, dyspareunia, dysuria, and pelvic pain), (endometriosis health profile-5) EHP-5 and (short form 12) SF-12 questionnaires before the day of the surgery. (12-14) A validated form of VAS score was used and scored from 0: No pain to 10: the worst pain all in their lives in a likert fashion. The VAS and (quality of life ) QoL questions were asked then in the 3rd and 6th month of during their follow up visits. A validated form of SF-12 that includes physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality (energy/fatigue) social functioning, role limitations due to emotional problems and mental health (psychological distress or wellbeing) were asked. The questions are scored and analysed using a statistical algorithm to give two scores: the physical component summary and the mental component summary.

A validated form of EHP-5 questionnaire was used to determine endometriosis related QoL of the patients. EHP-5 consists of two parts: the first has a central questionnaire that evaluate five dimensions - pain, control and powerlessness, emotional well-being, social support, and self-image; and the second part measuring the areas of sexual intercourse, work, relationship with children, feelings about medical professional, treatment and infertility.

Statistical analysis Data analysis was performed by using SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). A one-sample Kolmogorov-Smirnov test was performed to analyse the distribution of clinical variables. The frequency and percentage of the categorical variables and the mean, standard deviation, median and range values of the continuous and ordinal variables were presented. The study groups were compared using Student t test for parametric variables and Mann Whitney U test for the non-parametric variables. A post-hoc sample size calculation was performed via a two-sided Z test (α=0.05, β=0.20) for each study groups in order to obtain VAS scores as the primary outcome A p-value of < 0.05 was considered statistically significant for all calculations

Being tested
40 cc HyaRegen NCH gel, 40 cc sterile saline solution
Medical subject headings
Endometriosis, Tissue Adhesions

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 40 cc HyaRegen NCH gelDrug

    Also called bleeding control

    After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.

  • 40 cc sterile saline solutionDrug

    Also called bleeding control

    After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.

Study groups in NCT04023383
Study groupRoleWhat they receive
ControlPlacebo comparatorThe patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Receives: Drug: 40 cc sterile saline solution
HyaRegen NCH gel groupExperimentalIn the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
Receives: Drug: 40 cc HyaRegen NCH gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The preoperative and postoperative 3rd and 6th month change of Visual Analogue Scale symptom score

    A validated form of VAS score was used and scored from 0: No pain to 10: the worst pain all in their lives in a likert fashion.

    Measured: The preoperative and postoperative 6th month change in Visual Analogue Scale symptom score

Secondary outcomes (2)
  1. Short Form-12 Quality of Life

    A validated form of Short Form-12 Quality of Life that includes physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality (energy/fatigue) social functioning, role limitations due to emotional problems and mental health (psychological distress or wellbeing) were asked. The scores may be reported as Z-scores (difference compared to the population average, measured in standard deviations). We used an online programme (https://www.orthotoolkit.com/sf-12) to calculate Short Form-12 Quality of Life total and sub-scale results. The maximum PCS-12 (Physical Score) is 55.57 and the maximum MCS-12 (Mental Score) is 60.75. The minimum PCS-12 (Physical Score) is 22.99 and the minimum MCS-12 (Mental Score) is 19.06.

    Measured: The preoperative and postoperative 3rd and 6th month change of Short Form-12 Quality of Life questions were recorded considering follow up visits.

  2. Endometriosis Health Profile (EHP-5)

    A validated form of Endometriosis Health Profile (EHP-5)

    Measured: The preoperative and postoperative 3rd and 6th month change of A validated form of

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2019
  2. Study start1 Jan 2017
  3. Primary completion1 Jan 2019
  4. Study completion1 Jun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04023383
Sponsor's protocol ID
HYALOENDOQoL
Acronym
HYALOENDOQoL
Status last verified
Mar 2021
First submitted
13 Jul 2019
Last updated
15 Mar 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Arcoverde FVL, Andres MP, Borrelli GM, Barbosa PA, Abrao MS, Kho RM. Surgery for Endometriosis Improves Major Domains of Quality of Life: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2019 Feb;26(2):266-278. doi: 10.1016/j.jmig.2018.09.774. Epub 2018 Sep 20.

    PubMed 30244153

Questions about this trial

What is this clinical trial studying?

A study testing 40 cc HyaRegen NCH gel and 40 cc sterile saline solution in people with Endometriosis and Adhesion, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The preoperative and postoperative 3rd and 6th month change of Visual Analogue Scale symptom score (time frame: The preoperative and postoperative 6th month change in Visual Analogue Scale symptom score). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04023383, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in